<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01247116</url>
  </required_header>
  <id_info>
    <org_study_id>BSC-UOC-2009</org_study_id>
    <nct_id>NCT01247116</nct_id>
  </id_info>
  <brief_title>First-line Bosentan and Sildenafil Combination Therapy for Pulmonary Arterial Hypertension</brief_title>
  <official_title>First-line Bosentan and Sildenafil Combination Therapy for Pulmonary Arterial Hypertension: A Safety and Efficacy Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Calgary</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the strategy of initiating double oral combination&#xD;
      therapy with bosentan and sildenafil at the time of diagnosis of pulmonary arterial&#xD;
      hypertension (PAH) in a preliminary way.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current treatment paradigms for PAH suggest adopting goals of therapy with relatively&#xD;
      objective parameters such as 6 minute walk distance to determine when to add a second oral&#xD;
      agent (1). This often entails observing deterioration in the patient on a single agent before&#xD;
      instituting the second one. This strategy could be problematic, as patients may never recover&#xD;
      the function lost due to progressive PAH (2). In addition, given the malignant nature of the&#xD;
      clinical course of PAH in many cases and the nature of the underlying proliferative&#xD;
      vasculopathy, some have argued that altering this paradigm to resemble that used in cancer&#xD;
      chemotherapy may be more appropriate (3). That is, &quot;induction&quot; therapy at diagnosis with&#xD;
      multiple agents followed by a maintenance phase of treatment might offer significant benefits&#xD;
      to the patient.&#xD;
&#xD;
      This open-label pilot study is the first to investigate the potential efficacy and safety of&#xD;
      a first-line combination strategy in consecutive patients with PAH in contrast to the&#xD;
      &quot;add-on&quot; strategy for combination therapy. It will serve as the basis on which to consider&#xD;
      larger, multicenter investigations of this strategy.&#xD;
&#xD;
        1. Hoeper M, et al. Eur Respir J. 2005 Nov;26(5):858-63.&#xD;
&#xD;
        2. Halpern SD, et al. Proc Am Thorac Soc. 2008 Jul 15;5(5):631-5.&#xD;
&#xD;
        3. Provencher S, et al. Chest. 2005 Dec;128(6 Suppl):622S-628S.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>6 minute walk test distance</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>6 minute walk test distance</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic parameters</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamics</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life as measured by CAMPHOR questionnaire</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">12</enrollment>
  <condition>Hypertension, Pulmonary</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients with idiopathic pulmonary arterial hypertension (IPAH) or PAH&#xD;
        associated with connective tissue disease that are naive to PAH targeted therapies will be&#xD;
        enrolled.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with symptomatic Functional Class III PAH in the following categories:&#xD;
             Idiopathic (IPAH), Familial (FPAH), Associated with connective tissue disease,&#xD;
             Associated with drugs or toxins&#xD;
&#xD;
          -  PAH diagnosed by right heart catheterization, defined as: mean pulmonary arterial&#xD;
             pressure (mPAP) ≥ 25 mmHg, PVR &gt; 3 mmHg/l/min (Wood units) or &gt; 240 dyn sec cm-5,&#xD;
             pulmonary capillary wedge pressure (PCWP) ≤ 15 mmHg&#xD;
&#xD;
          -  Baseline 6 MWT distance &gt; 150 and &lt; 450 m&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with ERAs other than bosentan;&#xD;
&#xD;
          -  Treatment with PDE5 inhibitors other than sildenafil;&#xD;
&#xD;
          -  Treatment with any prostanoid;&#xD;
&#xD;
          -  PAH associated with thyroid disorders, glycogen storage disease, Gaucher disease,&#xD;
             hereditary hemorrhagic telangiectasia, hemoglobinopathies, myeloproliferative&#xD;
             disorders and splenectomy; valvular disease with valvular lesions to be excluded by&#xD;
             echocardiogram within 2 years prior to randomization&#xD;
&#xD;
          -  Restrictive lung disease: total lung capacity (TLC) &lt; 60% of normal predicted value;&#xD;
&#xD;
          -  Obstructive lung disease: forced expiratory volume/forced vital capacity (FEV1/FVC) &lt;&#xD;
             50%&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naushad Hirani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Calgary</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Calgary, Peter Lougheed Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T1Y 6J4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>November 23, 2010</study_first_submitted>
  <study_first_submitted_qc>November 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2010</study_first_posted>
  <last_update_submitted>June 9, 2018</last_update_submitted>
  <last_update_submitted_qc>June 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Calgary</investigator_affiliation>
    <investigator_full_name>Naushad Hirani</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

